http://www.facebook.com/notes.php?id=117471578700&s=40#!/note.php?note_id=428063081183


Gilenya, Novartis's new oral medication, receives FDA approval - Viewing Gilenya from the CCSVI perspective
written for CCSVI Alliance by Al Ossorio, http://www.ccsvi.org/   Gilenya, Novartis's new oral MS medication, was approved by the FDA on Tuesday, September 22nd.  From a CCSVI perspective, we often think of pharmaceutical approaches to MS as distant if not wholly separate from the C...